Guanine

Guanine

SCHEMBL101893

Nc1nc2nc[nH]c2c(=O)[nH]1.O=P(O)(O)OP(=O)(O)O

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PNP P00491 2/20 0.74
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
HPGD P15428 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GDA Q9Y2T3 1/20 0.45
GRIA1 P42261 1/20 0.43
GRIA2 P42262 1/20 0.43
GRIA3 P42263 1/20 0.43
GRIA4 P48058 1/20 0.43
POLB P06746 2/20 0.41
POLA1 P09884 1/20 0.40
POLG P54098 1/20 0.40
DPP4 P27487 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triphosphate SCHEMBL12813216 0.94 PNP (0.70) PNPALDH1A1KDM4EMEN1MAPT
Triphosphate SCHEMBL76054 0.94 PNP (0.70) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL29844110 0.93 PNP (0.68) PNPALDH1A1KDM4EMEN1MAPT
Triphosphate SCHEMBL28841044 0.93 PNP (0.68) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL101895 0.91 PNP (0.84) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL663746 0.91 PNP (0.84) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL76056 0.91 PNP (0.84) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL5372458 0.90 PNP (0.81) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL28840730 0.88 PNP (0.79) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL27448636 0.88 PNP (0.79) PNPALDH1A1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4087611-A1 SHP2 INHIBITOR DOSING AND METHODS OF TREATING CANCER Revolution Medicines, Inc. (US) 2022-11-16 EP claimed
CN-114929279-A Methods of administering SHP2 inhibitors and treating cancer 锐新医药公司 2022-08-19 CN claimed
US-20220110871-A1 PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE GLYCOMINE, INC. (US) 2022-04-14 US claimed
EP-3954360-A2 PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE Glycomine, Inc. (US) 2022-02-16 EP claimed
US-20200246266-A1 PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE GLYCOMINE, INC. (US) 2020-08-06 US claimed
WO-2019034597-A1 FORCE-RESPONSIVE POLYMERSOMES AND NANOREACTORS; PROCESSES UTILIZING THE SAME ADOLPHE MERKLE INSTITUTE, UNIVERSITY OF FRIBOURG (CH) 2019-02-21 WO claimed
US-20180036239-A1 PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE GLYCOMINE, INC. (US) 2018-02-08 US claimed
US-20160228364-A1 PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE GLYCOMINE, INC. (US) 2016-08-11 US claimed
EP-3046537-A2 PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE Glycomine, Inc. (US) 2016-07-27 EP claimed
WO-2015053910-A2 PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE GLYCOMINE LLC (US) 2015-04-16 WO claimed
US-20140329699-A1 SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION OXFORD FINANCE LLC, AS COLLATERAL AGENT 2014-11-06 US claimed
EP-2785868-A1 SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION Genapsys Inc. (US) 2014-10-08 EP claimed
WO-2013082619-A1 SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION GENAPSYS, INC. (US) 2013-06-06 WO claimed
US-8383597-B2 G proteins in tumor growth and angiogenesis CORNELL RESEARCH FOUNDATION, INC. (US) 2013-02-26 US claimed
US-8173620-B2 BHQ-caged nucleotide probes photolysable by two-photon excitation UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2012-05-08 US claimed
US-20100048502-A1 BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION NATIONAL SCIENCE FOUNDATION 2010-02-25 US claimed
CN-101495504-A Materials and methods for the generation of fully 2'-modified nucleic acid transcripts ARCHEMIX CORP (US) 2009-07-29 CN claimed
US-20080020994-A1 G proteins in tumor growth and angiogenesis CORNELL RESEARCH FOUNDATION, INC. (US) 2008-01-24 US claimed
US-20260094669-A1 EPITOPE PREDICTION VIA A LEARNED GENOTYPE NETWORK ACROSS CLASS II MHC ALLELES SEATTLE PROJECT CORP (US) 2026-04-02 US disclosed
WO-1994029727-A1 INHIBITING PROTEIN INTERACTIONS THE GENERAL HOSPITAL CORPORATION (US) 1994-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260094669-A1 EPITOPE PREDICTION VIA A LEARNED GENOTYPE NETWORK ACROSS CLASS II MHC ALLELES MICA, HLA-DRB1, TAP2 PNP 2841/4885ALDH1A1 4709/4885KDM4E 2641/4885
US-20100048502-A1 BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION NUDT1, RECQL, PNP PNP 3/4885ALDH1A1 1338/4885KDM4E 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.